Compare CVS Health Corp (CVS) vs Expensify Inc (EXFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Expensify Inc — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.49B), while Expensify Inc trades at $2.3 (market cap $206.99M). The key difference: CVS Health Corp is far larger — about 543.5× Expensify Inc's market cap, and CVS Health Corp pays a 3.02% dividend while Expensify Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Expensify Inc for 41 Days on average.
| CVS | EXFY | |
|---|---|---|
Market Cap | $112.49B | $206.99M |
Volume | 8,467,392 | 256,089 |
Sector | Health | Technology |
52-Week High | $110.60 | $2.72 |
52-Week Low | $70.08 | $0.75 |
Typical Hold Time | 83 Days | 41 Days |
Enterprise Value | $174.83B | $146.61M |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Expensify (EXFY) trades at $2.27, up 1.79% on the day, with a neutral technical signal and bullish moving averages. The company reported Q2 2026 earnings of $0.04 per share, beating estimates, and raised free cash flow guidance. Revenue trends show stabilization around $140M annually, though net income remains negative. Recent news highlights AI-native ERP integrations and European card expansion, signaling growth initiatives.
The outlook is mixed: analyst consensus is bullish with a $13.75 price target, but high P/E of 258.82 and persistent losses pose valuation risks. Investment opportunity lies in execution of AI-driven products and cash flow improvement, while key risks include competitive pressure and failure to achieve sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
